OBJECTIVES: Glucosamine and chondroitin supplements have been shown to have anti-inflammatory properties in both in vitro studies and animal models; however, little is known about these relationships in humans. The VITamins and Lifestyle (VITAL) biomarker study evaluated the associations between use of these supplements and a panel of circulating inflammatory biomarkers. DESIGN: Study participants included 217 men and women age 50-75 years living in the Seattle metropolitan area. Use of glucosamine and chondroitin supplements was ascertained by home interview/supplement inventory. Inflammation was assessed by using blood and urine collected at the time of home interview. Measures of systemic inflammation included plasma high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, soluble TNF receptors I and II, and urinary prostaglandin E2-metabolite (PGE-M). Multivariate-adjusted linear regression was used to evaluate the associations between supplement use and biomarkers of inflammation. RESULTS: High users (14 or more pills/week) of chondroitin had 36% lower hsCRP (ratio, 0.64; 95% confidence interval [CI], 0.39-1.04; p for trend=.03) and 27% lower PGE-M (ratio, 0.73; 95% CI, 0.5-0.98; p for trend=.07) than nonusers. Compared with nonusers, high users of glucosamine had 28% lower hsCRP (ratio, 0.72; 95% CI, 0.47-1.08; p for trend=.09) and 24% lower PGE-M (ratio, 0.76; 95% CI, 0.59-0.97; p for trend=0.10). Use of glucosamine and chondroitin supplements was not associated with the other markers of inflammation. CONCLUSIONS: These results support prior research suggesting that use of glucosamine and chondroitin is associated with reduced hsCRP and PGE2, but further work is needed to more definitively evaluate the anti-inflammatory potential of these supplements.
OBJECTIVES:Glucosamine and chondroitin supplements have been shown to have anti-inflammatory properties in both in vitro studies and animal models; however, little is known about these relationships in humans. The VITamins and Lifestyle (VITAL) biomarker study evaluated the associations between use of these supplements and a panel of circulating inflammatory biomarkers. DESIGN: Study participants included 217 men and women age 50-75 years living in the Seattle metropolitan area. Use of glucosamine and chondroitin supplements was ascertained by home interview/supplement inventory. Inflammation was assessed by using blood and urine collected at the time of home interview. Measures of systemic inflammation included plasma high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, soluble TNF receptors I and II, and urinary prostaglandin E2-metabolite (PGE-M). Multivariate-adjusted linear regression was used to evaluate the associations between supplement use and biomarkers of inflammation. RESULTS: High users (14 or more pills/week) of chondroitin had 36% lower hsCRP (ratio, 0.64; 95% confidence interval [CI], 0.39-1.04; p for trend=.03) and 27% lower PGE-M (ratio, 0.73; 95% CI, 0.5-0.98; p for trend=.07) than nonusers. Compared with nonusers, high users of glucosamine had 28% lower hsCRP (ratio, 0.72; 95% CI, 0.47-1.08; p for trend=.09) and 24% lower PGE-M (ratio, 0.76; 95% CI, 0.59-0.97; p for trend=0.10). Use of glucosamine and chondroitin supplements was not associated with the other markers of inflammation. CONCLUSIONS: These results support prior research suggesting that use of glucosamine and chondroitin is associated with reduced hsCRP and PGE2, but further work is needed to more definitively evaluate the anti-inflammatory potential of these supplements.
Authors: R Largo; M A Alvarez-Soria; I Díez-Ortego; E Calvo; O Sánchez-Pernaute; J Egido; G Herrero-Beaumont Journal: Osteoarthritis Cartilage Date: 2003-04 Impact factor: 6.576
Authors: May M Chou; Nathalie Vergnolle; Jason J McDougall; John L Wallace; Stephanie Marty; Val Teskey; Andre G Buret Journal: Exp Biol Med (Maywood) Date: 2005-04
Authors: Laine J Murphey; Myles K Williams; Stephanie C Sanchez; Loretta M Byrne; Ildiko Csiki; John A Oates; David H Johnson; Jason D Morrow Journal: Anal Biochem Date: 2004-11-15 Impact factor: 3.365
Authors: Emily White; Ruth E Patterson; Alan R Kristal; Mark Thornquist; Irena King; Ann L Shattuck; Ilonka Evans; Jessie Satia-Abouta; Alyson J Littman; John D Potter Journal: Am J Epidemiol Date: 2004-01-01 Impact factor: 4.897
Authors: Giuseppe M Campo; Angela Avenoso; Salvatore Campo; Alida M Ferlazzo; Domenica Altavilla; Alberto Calatroni Journal: Arthritis Res Ther Date: 2003-03-06 Impact factor: 5.156
Authors: Elizabeth D Kantor; Xuehong Zhang; Kana Wu; Lisa B Signorello; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci Journal: Int J Cancer Date: 2016-07-18 Impact factor: 7.396
Authors: Elizabeth D Kantor; Kelli O'Connell; Peter S Liang; Sandi L Navarro; Edward L Giovannucci; Mengmeng Du Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-03-01 Impact factor: 4.090
Authors: Elizabeth D Kantor; Christina C Newton; Edward L Giovannucci; Marjorie L McCullough; Peter T Campbell; Eric J Jacobs Journal: Cancer Causes Control Date: 2018-02-06 Impact factor: 2.506
Authors: Elizabeth D Kantor; Kelli O'Connell; Mengmeng Du; Chao Cao; Xuehong Zhang; Dong Hoon Lee; Yin Cao; Edward L Giovannucci Journal: J Altern Complement Med Date: 2020-12-07 Impact factor: 2.579
Authors: Sandi L Navarro; Emily White; Elizabeth D Kantor; Yuzheng Zhang; Junghyun Rho; Xiaoling Song; Ginger L Milne; Paul D Lampe; Johanna W Lampe Journal: PLoS One Date: 2015-02-26 Impact factor: 3.240
Authors: Julyana M S Martins; Lindolfo D Dos Santos Neto; Raiana A Noleto-Mendonça; Genilson B de Carvalho; Sarah Sgavioli; Fabyola Barros de Carvalho; Nadja S M Leandro; Marcos B Café Journal: Poult Sci Date: 2020-10-06 Impact factor: 3.352